Suddenly, birthdays have taken on much more importance among Duchenne muscular dystrophy patients. The difference between age five and age six could mean the difference between receiving the latest gene therapy and not ... at least for now.
Sarepta Therapeutics, Inc.’s recently launched gene therapy Elevidys (delandistrogene moxeparvovec-rokl) is indicated only for ambulatory four- and five-year-olds with...







